11-06-2020

Press release: New study reports positive results for Smartfish product in patients with declining cognitive function

OSLO, NORWAY AND LUND, SWEDEN, June 11, 2020.

A new study published today presents positive results from a 6-year-research project at University of California, Los Angeles, where a drink-based nutritional product from Smartfish AS was used as an add-on to pharmacological treatment in patients with declining cognitive function. The results further strengthen evidence that Smartfish’s high quality nutritional products can enhance clinical outcome.

The nutritional drink used in the current study is part of the Smartfish product family and is a juice-based nutritional drink produced with the company’s proprietary emulsion technology containing unique high levels of omega-3-fatty acids, vitamin D, whey protein and resveratrol. In the current study, published [today] in the Journal of Alzheimer’s Disease, researchers at the University of California, Los Angeles (UCLA) have evaluated whether a nutritional drink from Smartfish, in addition to a conventional treatment with cholinesterase inhibitors could delay the disease progression in patients who exhibited cognitive impairment. Results from the study indicate both short-term and long-term positive effects from the combined treatment in patients suffering from mild cognitive impairment, as shown by improvements in cognition and activities of daily living.

“The outcomes of the study are exciting and strengthens our core belief that high quality omega-3-fatty acid supplements in combination with targeted nutritional ingredients can play a role in enhancing the clinical impact of standard medical treatments. There is a growing interest in and understanding of this in the research community and it is encouraging that the researchers continuously choose our products for their studies”, says Mozhgan Dorkhan MD, PhD and Chief Scientific Officer at Smartfish.

“We consider the excellent standard and the composition of nutritional supplementation to be of outmost importance for our patients. Smartfish’s omega-3 drink has had a precise concentration of the essential docosahexaenoic acid as well as excellent maintenance of its quality and efficacy during the full length of our 6-year-long study with patients suffering from early Alzheimer disease”, says Milan Fiala, MD, UCLA.

To date, Smartfish has partaken as a collaborator in some 40 studies showing positive effects from Smartfish products, such as RemuneTM, NutrifriendTM and RechargeTM on metabolic health, mental health and muscle recovery among others.

Beside these collaborative studies, Smartfish has conducted two randomized, double-blinded and placebo-controlled trials where Remune was evaluated as a targeted medical nutritional product in non-small cell lung cancer and chronic obstructive lung disease. Both these clinical trials showed positive effects on patient outcome when Remune was combined with standard care.

A full list of all research studies where Smartfish has participated can be found here.

For more information, please contact
Mozhgan Dorkhan, Chief Scientific Officer of Smartfish, +46 731474331
Geir Harstad, CEO of Smartfish, tel + 46 763151160

Nyheter

10-09-2020

Press release: First patient recruited in research study investigating the ef ...

20-08-2020

Smartfish welcomes Mari Rivelsrud as our interim International Product Specia ...

18-08-2020

Uno Viberg has been appointed Product Development- and Quality manager of Sma ...

12-06-2020

Press release: In-depth analysis of clinical trial results shows that Smartfi ...

05-06-2020

Smartfish Annual Report 2019

24-05-2020

Smartfishdrikk kan forbedre embryokvaliteten hos par som gjennomgår IVF-behan ...

14-05-2020

Smartfish mot kommersielt gjennombrudd

24-04-2020

Rollen et sunt kosthold spiller for å støtte immunforsvaret

04-10-2019

Pressemelding: Smartfish starter utrulling av forbrukerhelseprodukter i Asia ...

09-09-2019

Press release: Smartfish initiates global collaboration with B. Braun, securi ...